{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:10:53Z","timestamp":1782907853269,"version":"3.54.5"},"reference-count":9,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.eprac.2022.01.010","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T10:12:15Z","timestamp":1643796735000},"page":"414-419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating Use of the Octreotide Acetate Pen Injector in a Summative Human Factors Validation Study"],"prefix":"10.1016","volume":"28","author":[{"given":"Anthony","family":"Andre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Squittieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyashodhan","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2022.01.010_bib2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pharmthera.2015.05.007","article-title":"Therapeutic uses of somatostatin and its analogues: current view and potential applications","volume":"152","author":"Rai","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.eprac.2022.01.010_bib3","doi-asserted-by":"crossref","first-page":"R551","DOI":"10.1530\/ERC-16-0151","article-title":"Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future","volume":"23","author":"\u00d6berg","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"16","key":"10.1016\/j.eprac.2022.01.010_bib4","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.2165\/11318510-000000000-00000","article-title":"Medical therapy of acromegaly: efficacy and safety of somatostatin analogues","volume":"69","author":"Feelders","year":"2009","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.eprac.2022.01.010_bib5","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.3390\/ijms20123049","article-title":"Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future","volume":"20","author":"Stueven","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.eprac.2022.01.010_bib6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2022.01.010_bib7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1530\/EC-16-0038","article-title":"Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues","volume":"5","author":"Follin","year":"2016","journal-title":"Endocr Connect"},{"issue":"3","key":"10.1016\/j.eprac.2022.01.010_bib8","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1177\/193229681000400304","article-title":"Practical aspects of insulin pen devices","volume":"4","author":"Pearson","year":"2010","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"1","key":"10.1016\/j.eprac.2022.01.010_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12969-020-00455-4","article-title":"Prefilled pen versus prefilled syringe: a pilot study evaluating two different methods of methotrexate subcutaneous injection in patients with JIA","volume":"18","author":"Roszkiewicz","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.eprac.2022.01.010_bib10","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2147\/PPA.S154181","article-title":"Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study","volume":"12","author":"Vermeire","year":"2018","journal-title":"Patient Prefer Adherence"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22000349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22000349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:12:48Z","timestamp":1761516768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X22000349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1530891X22000349"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2022.01.010","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating Use of the Octreotide Acetate Pen Injector in a Summative Human Factors Validation Study","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2022.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}